Anti-CD38 nanobodies as theranostic agents for multiple myeloma

被引：0
|
作者：
Duray, Elodie [1 ]
Lejeune, Margaux [1 ]
Dumoulin, Mireille [1 ]
D'Huyvetter, Matthias [2 ]
Caers, Jo [3 ]
机构：
[1] ULiege, Liege, Belgium
[2] Vrije Univ Brussel, Brussels, Belgium
[3] CHU Liege, Liege, Belgium
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-044
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [1] The Anti-CD38 Antibody Therapy in Multiple Myeloma
    Petrucci, Maria Teresa
    Vozella, Federico
    CELLS, 2019, 8 (12)
  • [2] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
    Saltarella, Ilaria
    Desantis, Vanessa
    Melaccio, Assunta
    Solimando, Antonio Giovanni
    Lamanuzzi, Aurelia
    Ria, Roberto
    Storlazzi, Clelia Tiziana
    Mariggio, Maria Addolorata
    Vacca, Angelo
    Frassanito, Maria Antonia
    CELLS, 2020, 9 (01)
  • [3] Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma
    De La Puente, Pilar
    Jin, Abbey
    Luderer, Micah John
    Muz, Barbara
    King, Justin A.
    Vij, Ravi
    Azab, Abdel Kareem
    BLOOD, 2016, 128 (22)
  • [4] DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma
    Richardson, P.
    Lokhorst, H.
    Palumbo, A.
    Nahi, H.
    Laubach, J.
    Gimsing, P.
    Lisby, S.
    Cakana, A.
    Brun, N. Constantin
    Plesner, T.
    DRUGS OF THE FUTURE, 2013, 38 (08) : 545 - 554
  • [5] Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?
    D'Agostino, Mattia
    Mina, Roberto
    Gay, Francesca
    LANCET HAEMATOLOGY, 2020, 7 (05): : E355 - E357
  • [6] The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
    Moreno, Laura
    Perez, Cristina
    Zabaleta, Aintzane
    Manrique, Irene
    Alignani, Diego
    Ajona, Daniel
    Blanco, Laura
    Lasa, Marta
    Maiso, Patricia
    Rodriguez, Idoia
    Garate, Sonia
    Jelinek, Tomas
    Segura, Victor
    Moreno, Cristina
    Merino, Juana
    Rodriguez-Otero, Paula
    Panizo, Carlos
    Prosper, Felipe
    San-Miguel, Jesus F.
    Paiva, Bruno
    CLINICAL CANCER RESEARCH, 2019, 25 (10) : 3176 - 3187
  • [7] Serological Investigation in a Multiple Myeloma Patient receiving Daratumumab (Anti-CD38)
    Oldfield, L.
    Ison, T.
    Lau, W.
    TRANSFUSION, 2016, 56 : 135A - 136A
  • [8] Safety and Tolerability of Anti-CD38 Monoclonal Antibodies (mAb) in Multiple Myeloma
    Thet, Aye
    Myint, Phyo Thazin
    Hadid, Tarik
    BLOOD, 2022, 140 : 12552 - 12553
  • [9] Comparison of anti-CD38 antibodies in vitro mechanisms of action in multiple myeloma
    Kinder, Michelle
    Ta, Mi
    Axel, Amy
    Wong, Amy
    Rudnick, Stephen
    de Goeij, Bart
    van Bueren, Jeroen Lammerts
    Babich, Alex
    Mendonca, Mark
    Sendecki, Jocelyn
    Chiu, Christopher
    Bellew, Kevin
    Kane, Colleen
    CANCER RESEARCH, 2019, 79 (13)
  • [10] With anti-CD38 in multiple myeloma, a survival benefit too long to be significant?
    Cazabat, Romain
    HEMATOLOGIE, 2024, 30 (06):
12345